Italia markets closed

Teva Pharmaceutical Industries Limited (TEVJF)

Other OTC - Other OTC Prezzo differito. Valuta in USD.
Aggiungi a watchlist
9,400,00 (0,00%)
Alla chiusura: 09:36AM EST

Teva Pharmaceutical Industries Limited

124 Dvora Hanevi’a Street
Tel Aviv 6944020
972 3 914 8213

SettoreDrug Manufacturers - Specialty & Generic
Impiegati a tempo pieno34.004

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Eliyahu Sharon KalifExecutive VP & CFO2,01MN/D1973
Mr. Eric DrapeExecutive Vice President of Global Operations1,91MN/D1962
Mr. Mark SabagExecutive Vice President of International Markets Commercial1,92MN/D1971
Mr. Richard D. FrancisPresident, CEO & DirectorN/DN/D1968
Mr. Amir WeissSenior VP & Chief Accounting OfficerN/DN/D1977
Ran MeirHead of Investor RelationsN/DN/DN/D
Mr. David M. StarkExecutive VP & Chief Legal OfficerN/DN/D1969
Kathleen VeitSenior Vice President, Global Compliance & Ethics OfficerN/DN/DN/D
Ms. Vikki ConwayActing Head of Global Human ResourcesN/DN/DN/D
Mr. Kevin C. MannixSenior Vice President of Investor RelationsN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.


Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. In addition, it focuses on the central nervous system (CNS), pain, respiratory, and oncology areas. The company's products portfolio in the CNS field comprises Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; and AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; respiratory therapeutic area includes ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease; and oncology therapeutic field consists of Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration with MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia, as well as a collaboration with Sanofi to co-develop and co-commercialize TEV-48574 asset, a novel anti-TL1A therapy for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Governance aziendale

L'ISS Governance QualityScore di Teva Pharmaceutical Industries Limited al 28 novembre 2023 è 2. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 3; diritti degli azionisti: 3; retribuzione: 2.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.